A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Grant Support Bookmark and Share

Current Grant Support for Don J. Diamond, PhD

02/10 - 01/16
5R01 AI063356-09 (Barry & Diamond)
NIAID Evaluation of Protective CMV Vaccines in Rhesus Macaques The major goal of this project is to construct and evaluate MVA-based vaccines that target the endocytic pathway of infection using a validated RhCMV challenge model that exhibits shedding and systemic infection.
Role: PD/Principal Investigator
 
06/15 - 05/19
Fortress (Coronado) Biosciences SRA 
Accelerating clinical development of CMVPepVax, CMV-MVA Triplex and CMVConVAX
Role: Principal Investigator
 
 
10/14 – 08/19
1R01HL122216 (Miller)
NIH
Inducing NK cells to remember and fight cancer
Provide regular consults and provide insight into the natural history of CMV infection in transplant recipients and the role of adaptive and innate immunity to control the infection. Pending Review.
Role: Co-Investigator
 
10/14 – 07/19
1R01CA181045-01
CMVPepVax to Protect HCT Recipients from Cytomegalovirus Infection
CMVPepVax will be comprehensively evaluated in HLA-A2 hematopoietic cell transplant (HCT) recipients to discover the optimal formula for immunizing both donors and recipients to prevent CMV viremia
Role: Principal Investigator
 
05/12 - 12/17
5R01 CA077544-13
NCI
Control of CMV infection post-HCT using attenuated MVA-based CMV subunit vaccine The major goal of this continuation project is to evaluate a multi-subunit CMV vaccine in human subjects including a safety study in healthy adults and a therapeutic trial in HCT recipients.
Role: Principal Investigator
 
05/13 – 04/17
R01 AI103960-02 (Diamond & Barry)
NIH
HCMV Vaccine produced from BAC-MVA that Blocks Epithelial and Fibroblast Entry The major goals are to construct an MVA expressing Human-UL128 pentamer using BAC-MVA technology, immunization of RhCMV-negative monkeys, and characterize humoral responses that inhibit CMV infection of fibroblasts and epithelial cells, with and without pp65-gB-MVA.
Role: PD/Principal Investigator (Contact)
 
04/12 – 08/15
Nesvig Foundation Optimizing shRNA Approaches for Control of Experimental Murine Lymphoma using Salmonella Delivery Systems The major goal of this project is to develop a gene-targeting silencing approach to attenuate B-cell lymphoma applicable to future clinical adaptation.
Role: Principal Investigator
 
07/13 – 06/16
R21 CA0174306-02
NIH
IDO-silencing Salmonella therapy for the treatment of primary and metastatic PDAC The major goal of the R21 is to evaluate and optimize an IDO-silencing Salmonella-based therapy (shIDO-ST) for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC).
Role: Principal Investigator
 
01/14–09/16
p53MVA Pipeline Project Award
Phase 1 study combining a p53MVA vaccine with ipilimumab and nivolumab
The p53-MVA vaccine will be given concurrently with other immunomodulatory agents, such as checkpoint inhibitor monoclonal antibodies (e.g. Ipilimumab and/or Nivolumab or Pembrolizumab), with the aim of extending disease progression-free survival.
Role: Principal Investigator

Grant Support

Current Grant Support for Don J. Diamond, PhD

02/10 - 01/16
5R01 AI063356-09 (Barry & Diamond)
NIAID Evaluation of Protective CMV Vaccines in Rhesus Macaques The major goal of this project is to construct and evaluate MVA-based vaccines that target the endocytic pathway of infection using a validated RhCMV challenge model that exhibits shedding and systemic infection.
Role: PD/Principal Investigator
 
06/15 - 05/19
Fortress (Coronado) Biosciences SRA 
Accelerating clinical development of CMVPepVax, CMV-MVA Triplex and CMVConVAX
Role: Principal Investigator
 
 
10/14 – 08/19
1R01HL122216 (Miller)
NIH
Inducing NK cells to remember and fight cancer
Provide regular consults and provide insight into the natural history of CMV infection in transplant recipients and the role of adaptive and innate immunity to control the infection. Pending Review.
Role: Co-Investigator
 
10/14 – 07/19
1R01CA181045-01
CMVPepVax to Protect HCT Recipients from Cytomegalovirus Infection
CMVPepVax will be comprehensively evaluated in HLA-A2 hematopoietic cell transplant (HCT) recipients to discover the optimal formula for immunizing both donors and recipients to prevent CMV viremia
Role: Principal Investigator
 
05/12 - 12/17
5R01 CA077544-13
NCI
Control of CMV infection post-HCT using attenuated MVA-based CMV subunit vaccine The major goal of this continuation project is to evaluate a multi-subunit CMV vaccine in human subjects including a safety study in healthy adults and a therapeutic trial in HCT recipients.
Role: Principal Investigator
 
05/13 – 04/17
R01 AI103960-02 (Diamond & Barry)
NIH
HCMV Vaccine produced from BAC-MVA that Blocks Epithelial and Fibroblast Entry The major goals are to construct an MVA expressing Human-UL128 pentamer using BAC-MVA technology, immunization of RhCMV-negative monkeys, and characterize humoral responses that inhibit CMV infection of fibroblasts and epithelial cells, with and without pp65-gB-MVA.
Role: PD/Principal Investigator (Contact)
 
04/12 – 08/15
Nesvig Foundation Optimizing shRNA Approaches for Control of Experimental Murine Lymphoma using Salmonella Delivery Systems The major goal of this project is to develop a gene-targeting silencing approach to attenuate B-cell lymphoma applicable to future clinical adaptation.
Role: Principal Investigator
 
07/13 – 06/16
R21 CA0174306-02
NIH
IDO-silencing Salmonella therapy for the treatment of primary and metastatic PDAC The major goal of the R21 is to evaluate and optimize an IDO-silencing Salmonella-based therapy (shIDO-ST) for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC).
Role: Principal Investigator
 
01/14–09/16
p53MVA Pipeline Project Award
Phase 1 study combining a p53MVA vaccine with ipilimumab and nivolumab
The p53-MVA vaccine will be given concurrently with other immunomodulatory agents, such as checkpoint inhibitor monoclonal antibodies (e.g. Ipilimumab and/or Nivolumab or Pembrolizumab), with the aim of extending disease progression-free survival.
Role: Principal Investigator
Overview
Beckman Research Institute of City of Hope is responsible for fundamentally expanding the world’s understanding of how biology affects diseases such as cancer, HIV/AIDS and diabetes.
 
 
Research Departments/Divisions

City of Hope is a leader in translational research - integrating basic science, clinical research and patient care.
 

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

City of Hope’s Irell & Manella Graduate School of Biological Sciences equips students with the skills and strategies to transform the future of modern medicine.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 


NEWS & UPDATES
  • A strict diet and insulin shots can’t always control type 1 diabetes. What people with the immune disorder really need are insulin-producing cells of their own – currently only available through a still-experimental procedure known as islet cell transplantation. A new clinical trial at City of Hope will m...
  • Approximately one in eight women will be diagnosed with breast cancer during her lifetime. Although the disease can have a profound impact on the patient and her loved ones, it can often be effectively treated with surgery, radiation therapy, hormone therapy and chemotherapy. Skin- and nipple-sparing surgeries,...
  • City of Hope is a leader in the diagnosis and treatment of skin cancer and precancerous conditions. Our multidisciplinary team of health care professionals takes an integrated approach to treating this disease by combining the latest research findings with outstanding patient care. In this podcast, Hans Schoell...
  • Patients with chronic lymphocytic leukemia may soon find themselves with improved treatment options. Interim results from a study not conducted at City of Hope suggest that, for patients with chronic lymphocytic leukemia, or CLL, a new oral drug given in combination with standard treatment significantly reduced...
  • The childhood journal of Kevin Chan, M.D., foreshadowed his future: At the tender age of 6, he wrote that he wanted to be a surgeon when he grew up. “I liked the idea of fixing broken arms and legs,” Chan said. “Back then, those were the procedures I could relate to.” Although his passion for […]
  • The outlook and length of survival has not changed much in the past 25 years for patients suffering from an aggressive form of pancreatic cancer known as pancreatic ductal adenocarcinoma (PDAC). These patients still have few options for therapy; currently available therapies are generally toxic and do not incre...
  • “With bladder cancer, the majority of patients that I see can be cured,” said urologist Kevin Chan, M.D., head of reconstructive urology at City of Hope. “The challenge is to get patients the same quality of life that they had before surgery.” To meet this challenge, Chan and the urologic team at City of Hope [...
  • Already pioneers in the use of immunotherapy, City of Hope researchers are now testing the bold approach to cancer treatment against one of medicine’s biggest challenges: brain cancer. This month, they will launch a clinical trial using patients’ own modified T cells to fight advanced brain tumors. One of but a...
  • Brain cancer may be one of the most-frightening diagnoses people can receive, striking at the very center of who we are as individuals. Further, it often develops over time, causing no symptoms until it’s already advanced. Listen to City of Hope Radio as Behnam Badie, M.D., director of the Brain Tumor Pro...
  • The whole is greater than the sum of its parts. It takes a village. No man is an island. Choose your aphorism: It’s a simple truth that collaboration usually is better than isolation. That’s especially true when you’re trying to introduce healthful habits and deliver health care to people at risk of disease and...
  • When Maryland Governor Larry Hogan announced earlier this week that he has the most common form of non-Hodgkin lymphoma, he was giving voice to the experience of more than 71,000 Americans each year. The announcement came with Hogan’s promise to stay in office while undergoing aggressive treatment for the...
  • The spine can be affected by many different kinds of tumors. Malignant, or cancerous, tumors can arise within the spine itself. Secondary spinal tumors, which are actually much more common, begin as cancers in another part of the body, such as the breast and prostate, and then spread, or metastasize, to the spi...
  • Although most cancer occurs in older adults, the bulk of cancer research doesn’t focus on this vulnerable and fast-growing population. City of Hope and its Cancer and Aging Research Team aim to change that, and they’re getting a significant boost from Professional Practice Leader Peggy Burhenn, R.N....
  • Liz Graef-Larcher’s first brain tumor was discovered by accident six years ago. The then-48-year-old with a long history of sinus problems and headaches had been sent for an MRI, and the scan found a lesion in her brain called a meningioma – a tumor that arises in the meninges, the layers of tissue that cover a...
  • The colon and rectum are parts of the body’s gastrointestinal system, also called the digestive tract. After food is digested in the stomach and nutrients are absorbed in the small intestine, the remaining material moves down into the lower large intestine (colon) where water and nutrients are absorbed. The low...